Drug intelligence / Profile preview

penetropine

Development stage
Unknown
Lead developer
Beijing Institute of Pharmacology and Toxicology
Modality
Small Molecules
Administration
Intravenous, Intramuscular
01

Overview

Penetropine, also known as phencynonate, is a small molecule muscarinic acetylcholine receptor antagonist developed by the Institute of Toxicology and Pharmacology at the Academy of Military Medical Sciences in China. Chemically a tropane derivative, it acts as an anticholinergic agent by competitively inhibiting the binding of acetylcholine to muscarinic receptors. The specific (R,R)-enantiomer, often formulated as a fumarate salt, has been investigated in clinical trials as an injectable treatment for the preoperative reduction of salivary and airway gland secretions. This application is intended to prevent respiratory complications such as aspiration and to maintain a clear airway during anesthesia and surgical procedures. While the racemic form of phencynonate is approved in China for the treatment of motion sickness, the development of the (R,R)-isomer focuses on optimizing the pharmacological profile for anesthetic and preoperative use.

Other names
phencynonatephencynonate fumarate苯环壬酯
02

Targets

M1 (Muscarinic acetylcholine receptor M1)CHRM4 (M4)CHRM3 (M3)CHRM5 (M5)CHRM2 (M2)

Beyond the preview

Go deeper on penetropine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on penetropine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call